IP Library Granted Patent US 8,791,083
Granted Patent B2
US 8,791,083 · App. 12/388,856 · Granted Jul 29, 2014

Chimeric oligomeric compounds comprising alternating regions of northern and southern conformational geometry

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,791,083
App. No.
12/388,856
Granted
Jul 29, 2014
Kind
B2
Abstract

The present invention relates to novel chimeric oligomeric compounds having a plurality of alternating regions having either RNA like having northern or 3′-endo conformational geometry (3′-endo regions) or DNA like having southern or C2′-endo/O4′-endo conformational geometry. The oligomeric compounds of the present invention have shown reduction in mRNA levels in multiple in vitro and in vivo assay systems and are useful, for example, for investigative and therapeutic purposes.

Claims (22)

1. A method of reducing cell surface expression of CD86 in an MH-S cell comprising contacting the cell with a compound having at least 5 separate regions, wherein each of the regions is a continuous sequence from 1 to 5 nucleosides each comprising a 3′-endo sugar conformational geometry or a continuous sequence of 1 to 4 2′-deoxyribonucleosides, and wherein each of the regions comprising from 1 to 4 2′-deoxyribonucleosides is internally located between two of the regions comprising 1 to 5 nucleosides each comprising a 3′-endo sugar conformational geometry or at one of the 3′ or 5′-termini, wherein the compound has a nucleobase sequence at least 90% complementary to SEQ ID NO. 10, and thereby reducing cell surface expression of CD86 in said MH-S cell; wherein said nucleosides comprising 3′-endo sugar conformational geometry comprise, independently, a 2′-substituent group selected from 2′-F, 2′-OCH 3 and 2′-MOE.

2. The method of claim 1 , wherein said compound has the motif 2-1- 1 -2- 1 -1- 1 -1- 1 -1- 1 -1- 1 -3- 2 , wherein bolded and underlined numbers represent sugar modified nucleosides, independently, comprising a 2′-substituent group selected from 2′-F, 2′-OCH 3 and 2′-MOE.

3. The method of claim 1 , wherein said compound has the motif 3 -2- 1 -3- 1 -3- 1 -3- 3 , wherein bolded and underlined numbers represent sugar modified nucleosides, independently, comprising a 2′-substituent group selected from 2′-F, 2′-OCH 3 and 2′-MOE.

4. The method of claim 1 , wherein said compound has the motif 3 -2- 1 -2- 1 -2- 1 -2- 1 -2- 3 , wherein bolded and underlined numbers represent sugar modified nucleosides, independently, comprising a 2′-substituent group selected from 2′-F, 2′-OCH 3 and 2′-MOE.

5. The method of claim 1 , wherein said compound has the motif 3 -3- 1 -2- 1 -2- 1 -3- 4 wherein bolded and underlined numbers represent sugar modified nucleosides, independently, comprising a 2′-substituent group selected from 2′-F, 2′-OCH 3 and 2′-MOE.

6. The method of claim 1 , wherein said compound has the motif 5 -2- 1 -2- 1 -2- 1 -1- 5 , wherein bolded and underlined numbers represent sugar modified nucleosides, independently, comprising a 2′-substituent group selected from 2′-F, 2′-OCH 3 and 2′-MOE.

7. The method of claim 1 , wherein said compound has the motif 2 -2- 1 -3- 1 -2- 1 -3- 3 , wherein bolded and underlined numbers represent sugar modified nucleosides, independently, comprising a 2′-substituent group selected from 2′-F, 2′-OCH 3 and 2′-MOE.

8. The method of claim 1 , wherein said compound has the motif 3 -3- 1 -2- 1 -3- 1 -2- 2 , wherein bolded and underlined numbers represent sugar modified nucleosides, independently, comprising a 2′-substituent group selected from 2′-F, 2′-OCH 3 and 2′-MOE.

9. The method of claim 1 , wherein said compound has the motif 3 -2- 1 -3- 1 -2- 1 -3- 4 , wherein bolded and underlined numbers represent sugar modified nucleosides, independently, comprising a 2′-substituent group selected from 2′-F, 2′-OCH 3 and 2′-MOE.

10. The method of claim 1 , wherein said compound has the motif 3 -2- 1 -3- 1 -3- 1 -3- 3 , wherein bolded and underlined numbers represent sugar modified nucleosides, independently, comprising a 2′-substituent group selected from 2′-F, 2′-OCH 3 and 2′-MOE.

11. The method of claim 1 , wherein said compound has the motif 3 -2- 1 -2- 1 -3- 1 -2- 1 -1- 3 , wherein bolded and underlined numbers represent sugar modified nucleosides, independently, comprising a 2′-substituent group selected from 2′-F, 2′-OCH 3 and 2′-MOE.

12. The method of claim 1 , wherein said compound has the motif 4 -3- 1 -4- 1 -3- 4 , wherein bolded and underlined numbers represent sugar modified nucleosides, independently, comprising a 2′-substituent group selected from 2′-F, 2′-OCH 3 and 2′-MOE.

13. The method of claim 1 , wherein said compound has the motif 3 -3- 2 -4- 2 -3- 3 , wherein bolded and underlined numbers represent sugar modified nucleosides, independently, comprising a 2′-substituent group selected from 2′-F, 2′-OCH 3 and 2′-MOE.

14. The method of claim 1 , wherein said compound has the motif 3 -1- 1 -1- 1 -1- 1 -1- 1 -1- 1 -1- 1 -1- 4 , wherein bolded and underlined numbers represent sugar modified nucleosides, independently, comprising a 2′-substituent group selected from 2′-F, 2′-OCH 3 and 2′-MOE.

15. The method of claim 1 , wherein said compound has the motif 3 -4- 1 -4- 1 -4- 3 , wherein bolded and underlined numbers represent sugar modified nucleosides, independently, comprising a 2′-substituent group selected from 2′-F, 2′-OCH 3 and 2′-MOE.

16. The method of claim 1 , wherein said compound has the motif 3 -3- 1 -2- 1 -3- 1 -3- 3 , wherein bolded and underlined numbers represent sugar modified nucleosides, independently, comprising a 2′-substituent group selected from 2′-F, 2′-OCH 3 and 2′-MOE.

17. The method of claim 1 , wherein said compound has the motif 3 -3- 1 -3- 1 -2- 1 -3- 3 , wherein bolded and underlined numbers represent sugar modified nucleosides, independently, comprising a 2′-substituent group selected from 2′-F, 2′-OCH 3 and 2′-MOE.

18. The method of claim 1 , wherein said compound has the motif 3 -2- 2 -1- 2 -1- 2 -1- 1 -2- 3 , wherein bolded and underlined numbers represent sugar modified nucleosides, independently, comprising a 2′-substituent group selected from 2′-F, 2′-OCH 3 and 2′-MOE.

19. The method of claim 1 , wherein said compound has the motif 3 -1- 3 -1- 2 -1- 2 -1- 2 -1- 3 ,

wherein bolded and underlined numbers represent sugar modified nucleosides, independently, comprising a 2′-substituent group selected from 2′-F, 2′-OCH 3 and 2′-MOE.

20. The method of claim 1 , wherein said compound has the motif 3 -1- 2 -1- 2 -1- 2 -1- 2 -1- 4 , wherein bolded and underlined numbers represent sugar modified nucleosides, independently, comprising a 2′-substituent group selected from 2′-F, 2′-OCH 3 and 2′-MOE.

21. The method of claim 1 , wherein said compound has the motif 1 -1- 1 -1- 1 -1- 1 -1- 1 -1- 1 -1- 1 -1- 1 -1- 1 -1- 2 , wherein bolded and underlined numbers represent sugar modified nucleosides, independently, comprising a 2′-substituent group selected from 2′-F, 2′-OCH 3 and 2′-MOE.

Assignments (1)
CHANGE OF NAME Recorded Jun 15, 2017
From: ISIS PHARMACEUTICALS, INC.
To: IONIS PHARMACEUTICALS, INC.
Reel/Frame 042832/0269 →